Mov Disord Vol 38, Suppl 1 Archives - Page 172 of 186 - MDS Abstracts

2023 International Congress
Effect of variants in COMT and UGT1A genes on clinical response in patients with Parkinson’s disease treated with opicapone
E. Ojeda-Lepe, S. García-Díaz, R. Díaz Belloso, L. Muñoz-Delgado, S. Jesús, MT. Periñán, B. Benítez Zamora, AD. Adarmes-Gómez, D. Macías-García, M. Martín-Bornez, M. Bonilla-Toribio, D. Buiza-Rueda, R. Pineda-Sánchez, F. Carrillo, P. Gómez-Garre, P. Mir (Seville, Spain)
Objective: To identify genetic variants associated with different clinical responses in patients with Parkinson’s disease(PD) treated with opicapone. Background: Opicapone is a catechol‐O‐methyltransferase(COMT) inhibitor used…
2023 International Congress
Low Vision Occupational Therapy for Parkinson’s Disease – A Pilot Study at the University of Alabama at Birmingham
C. Parker, M. Maher, J. Vice, L. Lieb, M. Dean (BIRMINGHAM, USA)
Objective: Assess usefulness of low vision occupational therapy (OT) in a small cohort of Parkinson’s disease (PD) patients. Background: PD patients report vision-related symptoms more…
2023 International Congress
WATCH-PD: Longitudinal Digital Assessments in Early Parkinson’s Disease
T. Kangarloo, ER. Dorsey, P. Auinger, D. Volfson, P. Padmanabhan, Y. Gong, B. Tracey, D. Stephenson, D. Anderson, J. Severson, M. Kostrzebski, P. Wilmot, Y. Pohlson, J. Cosman, J. Adams (Cambridge, USA)
Objective: To provide a longitudinal profile of early Parkinson’s disease (PD) progression using clinical and digital measures, and to evaluate the extent to which digital…
2023 International Congress
Risk of hallucinations and amantadine treatment in levodopa-induced dyskinesia patients with Parkinson’s disease: a meta-analysis of randomized controlled trials
M. Adil, T. Ahmad, M. Sharma (New Delhi, India)
Objective: The present meta-analysis aims to find out association between risk of hallucinations and amantadine treatment in levodopa-induced dyskinesia (LID) patients with Parkinson’s disease (PD).…
2023 International Congress
Cardiovascular autonomic function in GBA-associated Parkinson’s disease: a cross-sectional study
T. de Santis, A. Cocco, P. Polverino, V. Polvere, EM. Valente, A. Albanese (Rozzano, Italy)
Objective: To objectively assess cardiovascular autonomic function in patients with Parkinson’s disease (PD) carrying pathogenic variants of beta-glucocerebrosidase gene (GBA-PD) and compare to non-mutated PD…
2023 International Congress
3D Multi-Delay pCASL to Understand Perfusion Changes in Patients with Parkinson’s disease with Mild Cognitive Impairment
B. Thomas, Z. Mari, V. Mishra (Dallas, USA)
Objective: To understand perfusion changes in patients with Parkinson’s disease (PD) with well-characterized mild cognitive impairment (MCI) using 3D multi-delay pseudo-continuous Arterial Spin Labeling (pCASL)…
2023 International Congress
Double lesion magnetic resonance-guided focused ultrasound treatment for cervical dystonia: a pilot study of two targets combination based on clinical symptoms
R. Galimova, Y. Sidorova, I. Buzaev, S. Illarioshkin, S. Safin, G. Akhmadeeva, D. Nabiullina, D. Teregulova, D. Krekotin, K. Meshchanova (Ufa, Russian Federation)
Objective: to investigate the safety and efficacy of double lesion MRgFUS intervention for treating cervical drug-refractory dystonia based on clinical signs due to the hypothesis…
2023 International Congress
Cortical gamma oscillations in Parkinson’s disease: ipsi- and contralateral deep brain stimulation-induced entrainment
M. Shcherbakova, S. Cernera, A. Hahn, S. Little, P. Starr (San Francisco, USA)
Objective: To characterize deep brain stimulation (DBS) parameters for bilateral induction of cortical finely tuned gamma (FTG) via unilateral stimulation. Background: FTG oscillations are reported…
2023 International Congress
Ultra long-term outcome of deep brain stimulation (DBS) compared to botulinum toxin (BoNT) treatment in cervical dystonia (CD)
IM. Wedding, V. Siewers, IM. Skogseid (Oslo, Norway)
Objective: To compare residual symptoms and disease-specific quality of life (DS-QoL) in CD patients treated with DBS, or BoNT injections alone, for minimum 3 years.…
2023 International Congress
Cognitive profile of essential tremor patients: Beyond the cerebellar cognitive affective syndrome
A. Nasri, A. Rekik, S. Mrabet, Y. Abida, A. Souissi, A. Gharbi, I. Kacem, A. Gargouri, R. Gouider (Tunis, Tunisia)
Objective: To describe the cognitive profile of essential tremor (ET) patients and gain insight into its pathophysiological process. Background: Nowadays, ET is considered as a…